Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
Xingmei Liao, Yujie Fan, Chunxiu Zhong, Siru Zhao, Liangxu Guo, Wenjuan Tan, Junhua Yin, Rong Fan · 2023
Read Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B by Xingmei Liao, Yujie Fan, Chunxiu Zhong, Siru Zhao, Liangxu Guo, Wenjuan Tan, Junhua Yin, Rong Fan (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10688146.txt.
Description
Two standard hepatitis B drugs might also change how COVID-19 hits the patients who take them, a claim doctors have argued over. Xingmei Liao and seven co-authors compared the two in a 2023 study of chronic hepatitis B outpatients. They surveyed 630 patients between December 2022 and February 2023 about recent infection.
About 64 percent had caught COVID-19 in the past two months. None needed hospital care, oxygen, or intensive care, and most illnesses were mild or moderate. After matching patients so the drug groups looked alike, 400 remained. Infection rates were near equal between the entecavir and tenofovir groups, about 60 and 64 percent. Symptom rates matched too. The authors conclude the choice between these two hepatitis drugs does not seem to sway COVID-19 risk or severity.
Catalog record
| CREATOR | Xingmei Liao, Yujie Fan, Chunxiu Zhong, Siru Zhao, Liangxu Guo, Wenjuan Tan, Junhua Yin, Rong Fan |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |